Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Oluwole OO, Forcade E, Muñoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ, van Meerten T. Oluwole OO, et al. Among authors: nater j. Bone Marrow Transplant. 2024 Mar;59(3):366-372. doi: 10.1038/s41409-023-02169-z. Epub 2024 Jan 4. Bone Marrow Transplant. 2024. PMID: 38177222 Free PMC article.
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
Jain MD, Miklos DB, Jacobson CA, Timmerman JM, Sun J, Nater J, Fang X, Patel A, Davis M, Heeke D, Trinh T, Mattie M, Neumann F, Kim JJ, To C, Filosto S, Reshef R. Jain MD, et al. Among authors: nater j. Clin Cancer Res. 2023 Oct 13;29(20):4118-4127. doi: 10.1158/1078-0432.CCR-23-0916. Clin Cancer Res. 2023. PMID: 37527011 Free PMC article.
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
van Meerten T, Kuruvilla J, Song KW, Thieblemont C, Minnema MC, Forcade E, De Guibert S, Kersten MJ, Mutsaers PG, Wermke M, Zheng Y, Xue A, Winters JN, Nater J, Shen RR, Spooner C, Neumann F, Kim JJ, Topp MS. van Meerten T, et al. Among authors: nater j. Am J Cancer Res. 2024 Jun 15;14(6):2905-2920. doi: 10.62347/LLXR8002. eCollection 2024. Am J Cancer Res. 2024. PMID: 39005691 Free PMC article.
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Locke FL, et al. Among authors: nater j. Transplant Cell Ther. 2024 Nov;30(11):1065-1079. doi: 10.1016/j.jtct.2024.08.018. Epub 2024 Aug 24. Transplant Cell Ther. 2024. PMID: 39187161 Free article.
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.
Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, Baker M, Miller CA, Ferraro F, Chen DY, Smith AM, LaValle TA, Duncavage EJ, Chou J, Tam V, Benoun JM, Nater J, Scholler N, Milletti F, Vezan R, Bot A, Rossi JM, Singh N. Ghobadi A, et al. Among authors: nater j. Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705. Blood Adv. 2022. PMID: 35858291 Free PMC article. No abstract available.
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.
Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, Yang P, Morrison K, Coleman J, Malik F, Challita-Eid P, Karki S, Aviña H, Hubert R, Capo L, Snyder J, Moon SJ, Luethy R, Mendelsohn BA, Stover DR, Doñate F. Zhao H, et al. Among authors: nater j. Cancer Res. 2018 Apr 15;78(8):2115-2126. doi: 10.1158/0008-5472.CAN-17-3202. Epub 2018 Jan 30. Cancer Res. 2018. PMID: 29382707
139 results